Omission of Contralateral Systematic Biopsies in Unilateral Suspicious Prostate Cancer on Magnetic Resonance Imaging: Implications for Radiation Treatment Selection

IF 4.5 3区 医学 Q1 UROLOGY & NEPHROLOGY European Urology Open Science Pub Date : 2025-03-01 Epub Date: 2025-01-24 DOI:10.1016/j.euros.2025.01.006
Daniël L. van den Kroonenberg , Sanne J. Jonker , Auke Jager , Joëlle D. Stoter , Eva Schaake , Karel A. Hinnen , Wietse S.C. Eppinga , Ivo G. Schoots , Jochem R.N. van der Voort van Zyp , André N. Vis
{"title":"Omission of Contralateral Systematic Biopsies in Unilateral Suspicious Prostate Cancer on Magnetic Resonance Imaging: Implications for Radiation Treatment Selection","authors":"Daniël L. van den Kroonenberg ,&nbsp;Sanne J. Jonker ,&nbsp;Auke Jager ,&nbsp;Joëlle D. Stoter ,&nbsp;Eva Schaake ,&nbsp;Karel A. Hinnen ,&nbsp;Wietse S.C. Eppinga ,&nbsp;Ivo G. Schoots ,&nbsp;Jochem R.N. van der Voort van Zyp ,&nbsp;André N. Vis","doi":"10.1016/j.euros.2025.01.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and objective</h3><div>A combined approach of magnetic resonance imaging (MRI) targeted biopsies (TBx) and systematic biopsies (SBx) was recommended previously in patients with unilateral suspicious prostate cancer (PCa) on MRI. Yet, new PCa guidelines suggest that contralateral SBx can be omitted. It is unknown how this guideline modification impacts treatment selection. This study evaluates the value of contralateral SBx in radiation treatment selection in patients with unilateral suspicious lesions (Prostate Imaging Reporting and Data System [PI-RADS] ≥3) on MRI.</div></div><div><h3>Methods</h3><div>Case files of 80 patients with a unilateral suspicious lesion on diagnostic MRI who underwent TBx and bilateral SBx were collected. The cases were presented to four radiation oncologists twice: once with diagnostic information of bilateral SBx and TBx, and once with diagnostic information of ipsilateral SBx and TBx pathology results. Based on this information, external beam radiation treatment (EBRT) fractionation scheme, duration of androgen deprivation therapy (ADT), and feasibility of brachytherapy (monotherapy or brachyboost) were considered.</div></div><div><h3>Key findings and limitations</h3><div>After omitting information of contralateral SBx pathology results, selection of EBRT fractionation scheme and ADT duration changed in 14% (95% confidence interval [CI] 9.8–17) and 15% (95% CI 11–19) of cases, respectively. The feasibility of brachytherapy as monotherapy and brachyboost, respectively, changed in 11% (95% CI 7.9–15) and in 21% (95% CI 17–26) of cases, with overall poor interobserver variability for both diagnostic scenarios (Fleiss’ kappa 0.15 and 0.16).</div></div><div><h3>Conclusions and clinical implications</h3><div>Our findings indicate that omitting contralateral SBx has an impact on the treatment selection of patients who choose for radiation therapy as their treatment for locally confined PCa.</div></div><div><h3>Patient summary</h3><div>In patients with prostate cancer identified via magnetic resonance imaging on one side of the prostate, exclusion of prostate biopsies from the opposite side affected the selection of radiation treatment.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"73 ","pages":"Pages 17-23"},"PeriodicalIF":4.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Urology Open Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666168325000461","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective

A combined approach of magnetic resonance imaging (MRI) targeted biopsies (TBx) and systematic biopsies (SBx) was recommended previously in patients with unilateral suspicious prostate cancer (PCa) on MRI. Yet, new PCa guidelines suggest that contralateral SBx can be omitted. It is unknown how this guideline modification impacts treatment selection. This study evaluates the value of contralateral SBx in radiation treatment selection in patients with unilateral suspicious lesions (Prostate Imaging Reporting and Data System [PI-RADS] ≥3) on MRI.

Methods

Case files of 80 patients with a unilateral suspicious lesion on diagnostic MRI who underwent TBx and bilateral SBx were collected. The cases were presented to four radiation oncologists twice: once with diagnostic information of bilateral SBx and TBx, and once with diagnostic information of ipsilateral SBx and TBx pathology results. Based on this information, external beam radiation treatment (EBRT) fractionation scheme, duration of androgen deprivation therapy (ADT), and feasibility of brachytherapy (monotherapy or brachyboost) were considered.

Key findings and limitations

After omitting information of contralateral SBx pathology results, selection of EBRT fractionation scheme and ADT duration changed in 14% (95% confidence interval [CI] 9.8–17) and 15% (95% CI 11–19) of cases, respectively. The feasibility of brachytherapy as monotherapy and brachyboost, respectively, changed in 11% (95% CI 7.9–15) and in 21% (95% CI 17–26) of cases, with overall poor interobserver variability for both diagnostic scenarios (Fleiss’ kappa 0.15 and 0.16).

Conclusions and clinical implications

Our findings indicate that omitting contralateral SBx has an impact on the treatment selection of patients who choose for radiation therapy as their treatment for locally confined PCa.

Patient summary

In patients with prostate cancer identified via magnetic resonance imaging on one side of the prostate, exclusion of prostate biopsies from the opposite side affected the selection of radiation treatment.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
单侧可疑前列腺癌在磁共振成像上遗漏对侧系统活检:对放射治疗选择的影响
背景与目的磁共振成像(MRI)靶向活检(TBx)和系统活检(SBx)联合治疗单侧MRI可疑前列腺癌(PCa)患者。然而,新的前列腺癌指南建议可以忽略对侧SBx。目前尚不清楚该指南的修改如何影响治疗选择。本研究评价对侧SBx在单侧可疑病变(前列腺影像学报告与数据系统[PI-RADS]≥3)MRI患者放射治疗选择中的价值。方法收集80例单侧可疑病变诊断MRI行TBx和双侧SBx的病例资料。病例两次向4位放射肿瘤学家报告,一次提供双侧SBx和TBx的诊断信息,一次提供同侧SBx和TBx的病理结果诊断信息。基于这些信息,我们考虑了外束放射治疗(EBRT)分次方案、雄激素剥夺治疗(ADT)持续时间以及近距离治疗(单次治疗或近距离增强)的可行性。在忽略对侧SBx病理结果信息后,选择EBRT分离方案和ADT持续时间分别改变了14%(95%置信区间[CI] 9.8-17)和15% (95% CI 11-19)的病例。分别在11% (95% CI 7.9-15)和21% (95% CI 17-26)的病例中,近距离治疗作为单药治疗和近距离增强治疗的可行性发生了变化,两种诊断方案的观察者间可变性总体较差(Fleiss ' kappa 0.15和0.16)。结论和临床意义我们的研究结果表明,忽略对侧SBx会影响局部局限性前列腺癌患者选择放射治疗的治疗选择。对于单侧前列腺磁共振成像确诊的前列腺癌患者,排除对侧前列腺活检影响放射治疗的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
European Urology Open Science
European Urology Open Science UROLOGY & NEPHROLOGY-
CiteScore
3.40
自引率
4.00%
发文量
1183
审稿时长
49 days
期刊最新文献
Reduced Rate of Complications With Transperineal Prostate Biopsy: Real-world Data From a National Cohort Derived From the Danish Prostate Cancer Registry Familial Risks in 317 000 Patients With Prostate Cancer in Relation to Metastases and Survival-Guiding Diagnostics Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors Who, When, and How: Watchful Waiting in the ERSPC Rotterdam A Study to Evaluate Efficacy and Safety of Hydeal Cyst Intravesical Instillations in Non–muscle Invasive Bladder Cancer Patients Treated With Intravesical Chemotherapy or Immunotherapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1